WS
LAB icon

Wedbush Securities’s Standard BioTools LAB Stock Holding History

Wedbush Securities’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-11,000
Closed -$44K – 856
2017
Q2 		$44K Sell
11,000
-900
-8% -$4.27K 0.01% 808
2017
Q1 		$68K Buy
+11,900
New +$75.4K 0.01% 790
2016
Q4 		– Sell
-11,000
Closed -$88K – 859
2016
Q3 		$88K Buy
+11,000
New +$101K 0.01% 760

Other funds holding LAB

LCS
Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wedbush Securities's LAB Position: Q3 2017 in Review

Wedbush Securities sold out of Standard BioTools (LAB) in Q3 2017, closing a stake of 11,000 shares — an estimated $44K sold.

Wedbush Securities first reported a position in LAB in Q3 2016 and held it in 3 quarters. The position peaked at $88K in Q3 2016. 80 funds tracked by Wall St. Rank hold LAB as of Q3 2017.

  • Wedbush Securities reported no remaining Standard BioTools position as of Q3 2017 after selling out during the quarter.
  • Wedbush Securities sold 11,000 Standard BioTools shares in Q3 2017, an estimated $44K.
  • Wedbush Securities first reported a position in Standard BioTools in Q3 2016 and held it in 3 quarters.
  • Wedbush Securities's Standard BioTools position peaked at $88K in Q3 2016.
  • 80 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2017.

Based on Wedbush Securities's 13F filing for Q3 2017, filed 31 Oct 2017.